| NiCure for the treatment of cartilage-related diseases, focusing on the treatment of Osteoarthritis; A technology of Mor Research Applications, the TTO of Clalit Health Services, Israel's largest HMO with approximately 4 million members HERZELIYA, Israel, November 3, 2011 /PRNewswire/ -- On November 2, 2011, XTL Biopharmaceuticals, Ltd. (the "Company") announced that it entered into a term sheet by which it will acquire a technology ("NiCure") from Mor Research Applications, the Technology Transfer ...continued XTLBY |
Thursday, November 3, 2011
XTL Biopharmaceuticals to Acquire NiCure
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment